1. Home
  2. BGC vs LQDA Comparison

BGC vs LQDA Comparison

Compare BGC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGC Group Inc.

BGC

BGC Group Inc.

HOLD

Current Price

$11.54

Market Cap

5.3B

Sector

Finance

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$85.16

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGC
LQDA
Founded
1945
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
5.5B
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
BGC
LQDA
Price
$11.54
$85.16
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$41.00
AVG Volume (30 Days)
2.3M
1.4M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
0.72%
N/A
EPS Growth
24.00
51.81
EPS
0.17
0.52
Revenue
$2,941,460,000.00
$158,320,000.00
Revenue This Year
$22.26
$278.87
Revenue Next Year
$7.03
$57.13
P/E Ratio
$69.21
$167.10
Revenue Growth
29.99
1031.18
52 Week Low
$8.27
$17.82
52 Week High
$12.89
$91.10

Technical Indicators

Market Signals
Indicator
BGC
LQDA
Relative Strength Index (RSI) 53.45 59.67
Support Level $10.47 $70.28
Resistance Level $11.91 $91.10
Average True Range (ATR) 0.32 5.47
MACD 0.04 -0.02
Stochastic Oscillator 59.43 71.85

Price Performance

Historical Comparison
BGC
LQDA

About BGC BGC Group Inc.

BGC Group Inc is a brokerage and financial technology company that serves financial markets, energy, and commodities markets. Its service and product offerings include brokerage for a wide range of financial products, including fixed income, equities, commodities, derivatives, and real estate, software solutions for trading platforms, clearing, trade execution, and other back-office services. Its clients mostly include banks, financial institutions, and corporate clients. BGC operates in one reportable segment, which is providing brokerage services. Geographically, the company generates a majority of its revenue from Europe, the Middle East and Africa (EMEA), followed by the Americas and the Asia-Pacific region.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: